| Species |
Human |
| Protein Construction |
TRAIL R4/TNFRSF10D (Ala56-His211)
Accession # Q9UBN6 |
His |
Avi |
| N-term |
|
C-term |
|
| Conjugate |
Biotin |
| Purity |
> 95% as determined by BisTris PAGE
> 95% as determined by HPLC |
| Endotoxin Level |
Less than 1EU per μg by the LAL method. |
| Biological Activity |
Measured by its binding ability in a functional ELISA. Immobilized Human TRAIL, No Tag at 5μg/ml (100μl/well) on the plate can bind TRAIL R4/TNFRSF10D[Biotin], His & Avi, Human. Test result was comparable to standard batch. |
| Expression System |
HEK293 |
| Theoretical Molecular Weight |
19.4 kDa |
| Apparent Molecular Weight |
Due to glycosylation, the protein migrates to 38-50 kDa based on Bis-Tris PAGE result. |
| Formulation |
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). |
| Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background |
TNF-related apoptosis inducing ligand (TRAIL) is a potential antitumor protein known for its ability to selectively eliminate various types of tumor cells without exerting toxic effects in normal cells and tissues. TRAIL-R2/DR5 as well as TRAIL-R3/DcR1 and TRAIL-R4/DcR2 were significantly higher expressed in advanced tumour stages. |
| Synonyms |
CD264; RSF10D; TRAILR4; DCR2; TRUNDD; TNFRSF10D |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
